Literature DB >> 7949468

Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents.

L J Zwi1, B C Baguley, J B Gavin, W R Wilson.   

Abstract

To determine whether xanthenone acetic acid (XAA) analogues of flavone acetic acid (FAA) have similar ischemic and nonischemic mechanisms of antitumor action to FAA, a series of such compounds was evaluated in vivo and in vitro. Necrotising activity and changes in tumor blood flow were measured in Colon 38 tumors, and morphological changes assessed in immune cell-infiltrated EMT6 tumor cell spheroids, after treatment with FAA, XAA and its derivatives (5-methyl XAA, 5,6-dimethyl XAA, 3-O-methyl XAA, 8-methyl XAA and xanthenone-4,5-diacetic acid). FAA, XAA and the 5-methyl and 5,6-dimethyl analogues of XAA were active in inducing tumor necrosis, falls in tumor perfusion and characteristic morphological changes in multicellular spheroids. The other XAA analogues lacked these activities. 5-methyl XAA and 5,6-dimethyl XAA were more potent than FAA or XAA. The results suggest that XAA and its analogues have the same mechanisms of action as FAA, and that both the vascular and the immune effects of these compounds are mediated via a common biochemical receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949468

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  18 in total

Review 1.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 2.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

Review 3.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors:  Bruce C Baguley; Dietmar W Siemann
Journal:  Expert Opin Investig Drugs       Date:  2010-11       Impact factor: 6.206

Review 4.  5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Authors:  Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).

Authors:  Liang-Chuan S Wang; Lotte Thomsen; Rachel Sutherland; Charu B Reddy; Sofian M Tijono; Chun-Jen J Chen; Catherine E Angel; P Rod Dunbar; Lai-Ming Ching
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

6.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

8.  Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Authors:  S M Tijono; K Guo; K Henare; B D Palmer; L-C S Wang; S M Albelda; L-M Ching
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

9.  Vascular disrupting agent drug classes differ in effects on the cytoskeleton.

Authors:  Sujeong Kim; Leonid Peshkin; Timothy J Mitchison
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

10.  Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Authors:  M J McKeage; J Von Pawel; M Reck; M B Jameson; M A Rosenthal; R Sullivan; D Gibbs; P N Mainwaring; M Serke; J-J Lafitte; C Chouaid; L Freitag; E Quoix
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.